PUNE, India, October 31, 2016 /PRNewswire/ --
ReportsnReports.com adds "Postherpetic Neuralgia - Pipeline Review,H2 2016" to its store providing an overview of the Postherpetic Neuralgia's therapeutic pipeline with comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics
Complete report on H2 2016 pipeline review of Postherpetic Neuralgia with 32 market data tables and 15 figures, spread across 98 pages is available at http://www.reportsnreports.com/reports/729116-postherpetic-neuralgia-pipeline-review-h2-2016.html.
Postherpetic neuralgia is a complication of shingles, which is caused by the chickenpox (herpes zoster) virus. Signs and symptoms may include pain, sensitivity to light touch, itching and numbness and weakness or paralysis. The predisposing factors include age, people with HIV and Hodgkin's lymphoma. Treatment includes anticonvulsants, antidepressants and opioid painkillers. Postherpetic Neuralgia pipeline therapeutics constitutes close to 23 molecules. which approximately 23 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 3, 7 and 1 respectively.
The report outlays comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Companies discussed in this Postherpetic Neuralgia Pipeline Review, H2 2016 report include Aestus Therapeutics, Inc., ContraVir Pharmaceuticals, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Immune Pharmaceuticals Inc., Jiangsu Hengrui Medicine Co., Ltd., KPI Therapeutics, Inc., Lpath, Inc., Merck & Co., Inc., Patagonia Pharmaceuticals, LLC, Pfizer Inc., Phosphagenics Limited, Relmada Therapeutics, Inc., Scilex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. and Toray Industries, Inc. Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=729116.
Drug Profiles mentioned in this research report are (amitriptyline + ketamine hydrochloride), (clonidine hydrochloride + naltrexone hydrochloride), ATX-08001, bupivacaine hydrochloride, C-746, DWP-05195, funapide, FV-100, ketoprofen, lidocaine hydrochloride, lidocaine hydrochloride patch, Lpathomab, mepivacaine hydrochloride, mirogabalin besylate, MK-8291, naltrexone hydrochloride, PATN-02, pregabalin CR, pregabalin SR, REL-1017, TRK-700, U-2902 and zucapsaicin.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Another newly published market research report titled on Pulmonary Fibrosis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are AdAlta Pty Ltd., Advinus Therapeutics Ltd, Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Asahi Kasei Pharma Corp., aTyr Pharma, Inc., Biogen Inc, Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Celgene Corporation, Chrysalis Pharma SAS, Clanotech AB, Compugen Ltd., Cynata Therapeutics Limited, Diffusion Pharmaceuticals Inc., Digna Biotech, S.L., Elsalys Biotech SAS, F. Hoffmann-La Roche Ltd., FibroGen, Inc., FibroStatin SL, Galapagos NV, Galectin Therapeutics, Inc., GenKyoTex S.A., GlaxoSmithKline Plc, Global Blood Therapeutics, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Yuhan Corporation etc. Pulmonary Fibrosis Pipeline market research report of 377 pages is available at http://www.reportsnreports.com/reports/729115-pulmonary-fibrosis-pipeline-review-h2-2016.html.
Explore more reports on Pharmaceuticals.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact: Ritesh Tiwari 2nd floor, metropole, Next to Inox theatre, Bund garden road Pune-411001 Maharashtra, India Tel: +1-888-391-5441 [email protected]
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml
Subscribe to our Free Newsletters!
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.